Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
AbbVie Inc., ABBV
Summary: AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
- Last Price: $181.20
- Price Change: $1.34, 0.75%
- Yearly Gain: 17.78%
- Market Cap: $320.08B
- P/E Ratio: 66.62
Here are 3rd party ratings for ABBV:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 24% (192 out of 252)
What is the sentiment on the street regarding AbbVie Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in ABBV or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ABBV before you decide to make any investment.
Click here for chart >>
Neurocrine Biosciences, Inc., NBIX
Summary: Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
- Last Price: $139.16
- Price Change: $-2.64, -1.86%
- Yearly Gain: 45.75%
- Market Cap: $13.85B
- P/E Ratio: 56.34
Here are 3rd party ratings for NBIX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (90 out of 252)
What is the sentiment on the street regarding Neurocrine Biosciences, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in NBIX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on NBIX before you decide to make any investment.
Click here for chart >>
Jazz Pharmaceuticals plc, JAZZ
Summary: Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
- Last Price: $118.30
- Price Change: $0.53, 0.45%
- Yearly Gain: -12.55%
- Market Cap: $7.38B
- P/E Ratio: 19.39
Here are 3rd party ratings for JAZZ:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 36% (90 out of 252)
What is the sentiment on the street regarding Jazz Pharmaceuticals plc ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Negative
- Hedge Fund signal: Medium Risk
If you are interested in JAZZ or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on JAZZ before you decide to make any investment.
Click here for chart >>
Exelixis, Inc., EXEL
Summary: Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.
- Last Price: $22.61
- Price Change: $-0.46, -1.99%
- Yearly Gain: 29.42%
- Market Cap: $6.86B
- P/E Ratio: 34.78
Here are 3rd party ratings for EXEL:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding Exelixis, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in EXEL or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on EXEL before you decide to make any investment.
Click here for chart >>
Thanks for reading!